Search

Tosedostat

Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

Alvimopan

Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.

Mirococept

It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

Troxacitabine

There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

Diaziquone

Phosphocysteamine

PX-478

PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

Gallium maltolate

Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

CRx-401

has proven to be well tolerated in clinical trials. … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose

Pucotenlimab

It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.